Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Fig. 1

AL355338 was upregulated in aggressive NSCLC tissues and predicted poor prognosis. A AL355338 expression was analyzed by qRT-PCR in NSCLC samples and adjacent non-tumor tissues (n = 80). B AL355338 expression in metastatic (mNSCLC) samples (n = 65) and non-metastatic (nmNSCLC) samples (n = 15) was measured by qRT-PCR. C Relative AL355338 expression levels in different TNM stages. D Survival was analyzed and compared between patients with low and high levels of AL355338 in 80 NSCLC patients, log-rank test. E Representative FISH images of AL355338 expression in NSCLC tumor tissues and in different TNM stages (blue, DAPI; red, positive staining). Scale bar, 100 μm. F Statistical analysis of AL355338 expression in stage I + II group and in stage III + IV group. G, H Univariate analysis (G) and multivariate analysis (H) of AL355338 were performed in our NSCLC cohort. All the bars correspond to 95% confidence intervals. Data shown are mean ± SD (n = 3) (*P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page